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Purpose: Photothermal therapy (PTT) exploits the light-absorbing properties of nanomater-
ials such as silica-gold nanoshells (NS) to inﬂict tumor death through local hyperthermia.
However, in in vivo studies of PTT, the heat distribution is often found to be heterogeneous
throughout the tumor volume, which leaves parts of the tumor untreated and impairs the
overall treatment outcome. As this challenges PTT as a one-dose therapy, this study here
investigates if giving the treatment repeatedly, ie, fractionated PTT, increases the efﬁcacy in
mice bearing subcutaneous tumors.
Methods: The NS heating properties were ﬁrst optimized in vitro and in vivo. Two
fractionated PTT protocols, consisting of two and four laser treatments, respectively, were
developed and applied in a murine subcutaneous colorectal tumor model. The efﬁcacy of the
two fractionated protocols was evaluated both by longitudinal monitoring of tumor growth
and, at an early time point, by positron emission tomography (PET) imaging of 18F-labeled
glucose analog 18F-FDG.
Results: Overall, there were no signiﬁcant differences in tumor growth and survival between
groups of mice receiving single-dose PTT and fractionated PTT in our study. Nonetheless,
some animals did experience inhibited tumor growth or even complete tumor disappearance
due to fractionated PTT, and these animals also showed a signiﬁcant decrease in tumor
uptake of 18F-FDG after therapy.
Conclusion: This study only found an effect of giving PTT to tumors in fractions compared
to a single-dose approach in a few animals. However, many factors can affect the outcome of
PTT, and reliable tools for optimization of treatment protocol are needed. Despite the modest
treatment effect, our results indicate that 18F-FDG PET/CT imaging can be useful to guide
the number of treatment sessions necessary.
Keywords: hyperthermia, cancer, nanoparticle, photothermal therapy, fractionated therapy,
positron emission tomography
Introduction
For years there has been growing interest in utilizing nanomedicine in cancer
diagnostics and therapy.1,2 One emerging approach within cancer nanomedicine is
photothermal therapy (PTT). PTT relies on light-absorbing nanoparticles which are
able to transform light into heat when irradiated with a resonant external light source,
thereby causing tumor death through local hyperthermia.3,4 To achieve efﬁcient
delivery of light to a nanoparticle-laden tumor and minimize unspeciﬁc heating, near-
infrared (NIR) laser light is commonly used as it has the lowest absorption and
deepest penetration in tissue.5 Delivery of nanoparticles to the tumor tissue is in
general based on passive accumulation facilitated through the enhanced permeability
and retention (EPR) effect, which is a consequence of the leaky character of tumor
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vessels and poor lymphatic drainage.6–8 Because the indi-
vidual components of the therapy are unharmful (the nano-
particles are inert and biocompatible, and the applied NIR
laser dose is non-phototoxic), the therapeutic effect is only
achieved in the tumor where the two are combined, making
PTT highly controlled and localized.
Despite its promising capability to selectively ablate
malignant tissue, PTT is still a fairly new approach that in
most cases only has been performed successfully on animals
with very small tumors.9–13 Eradicating larger and more
clinically relevant tumors without recurrence has proven
more difﬁcult.14,15 One major reason for this is that larger
tumors generally contain hypoxic regions with reduced blood
perfusion, and this, together with high interstitial pressure,
prevents nanoparticle delivery. The uneven nanoparticle dis-
tribution and the limited laser penetration depth lead to
inhomogeneous intratumoral heat distribution during PTT,
which also decays from the dermal surface in the direction of
the externally applied laser and makes it difﬁcult to ablate all
cancer cells simultaneously.16 Circumventing these chal-
lenges is not an easy ﬁx, and brings up the question if the
standard treatment protocol for PTT provides sufﬁcient ther-
apeutic efﬁcacy for clinical applications. This has motivated
researchers into studying an alternative use of PTT for com-
bination therapies, for example to enhance chemotherapeutic
efﬁcacy, to release anticancer agents, or to induce an immune
response for immunotherapy.9,17–20 There are also
approaches where enhanced irradiation doses are enabled
by combining indirect heating of the tumor with tissue sur-
face cooling, thereby preventing unspeciﬁc heating and treat-
ment-associated pain.21 Another strategy that has been
suggested is to give the treatment in low-dose fractions
instead of a single-dose, thereby killing cancer cells that
survived the ﬁrst treatment in following treatments and
avoiding surface overheating.22–26
In a recent study,27 we used PTT to treat mice-bearing
subcutaneous murine colon carcinoma tumors (CT26
tumors) using NIR resonant silica-gold nanoshells (NS),
which are the most widely used nanoparticles for both
preclinical studies and clinical trials of PTT.28–32 We
found that, in spite of reaching temperatures during treat-
ment that were above the threshold for cellular ablation, it
did not result in complete tumor removal in more than
a few mice. Furthermore, we observed unspeciﬁc heating
in laser irradiated control groups of up to 45°C, preventing
us from increasing the laser dose even further to enhance
the treatment response. Hence, in this study we investi-
gated in the same model and setup if there is a beneﬁt of
giving fractionated treatments. We ﬁrst examined the abil-
ity of the NS to heat under different laser intensities in an
in vitro setup, and conﬁrmed that they could in fact
undergo repeated heating sessions, a requirement for frac-
tionated therapy. Following this, we investigated if unspe-
ciﬁc heating could be eliminated by the use of an index
matching agent in NIR irradiated tumors in mice. Finally,
we evaluated and compared the treatment effect of two
different protocols for fractionated PTT in tumor-bearing
mice, using either two or four repeated treatment sessions.
In addition, as our previous study showed that
18F-ﬂuorodeoxyglucose (18F-FDG) positron emission
tomography/computed tomography (PET/CT) imaging
could be used for early non-invasive monitoring of PTT
outcome,33 this was implemented for evaluation of the
fractionated protocols.
Materials and methods
Nanoparticles
The 800 nm Resonant BioPureTM Gold NS, consisting of a
silica core surrounded by a thin gold shell, were obtained
from NanoComposix, USA. The NS were functionalized
with 5 kDa poly(ethylene glycol).
For the in vitro experiments, lot number JLF0015 was
used. The total diameter of the NS detected through trans-
mission electron microscopy (TEM) was reported by the
supplier as 150±9 nm, the diameter of the silica core was
119±5 nm, and the zeta potential was −34 mV.
Lot number JCP1545was used for the animal experiments.
The total diameter of the particles was reported as 157±9 nm,
and the diameter of the silica core was 119 nm±5 nm, with
a zeta potential of −42 mV.
In vitro experiments
To study the heating ability of NS under NIR light in vitro,
a solution of 5×109 NS/mL in water was prepared in a 1 mm
plastic cuvette. The cuvette was placed under the laser beam,
and the sample irradiated for 10 minutes at three different
laser powers (1.2, 1.5, and 1.8 W/cm2). Thereafter the solu-
tionwas left to cool off for another 10minutes. To study if the
NS could be reheated, a sample was prepared containing
5×109 NS/mL, and four cycles of irradiation of 10
minutes each followed by 10 minutes of cooling off were
performed (laser intensity of 1.5 W/cm2). Afterwards, the
sample was collected and TEM performed by qualiﬁed per-
sonnel at the Core Facility for IntegratedMicroscopy, Panum
Institute, University of Copenhagen. For both in vitro studies,
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the temperature in the solution wasmonitored real-time using
thermographic imaging, where images were taken every 30
seconds with a thermal camera (FLIR T-440 camera). The
images were analyzed within the FLIR tools software. For
the UV-vis spectra, 20 µL of the stock solution of nanopar-
ticles were dissolved in 4 mL of water. Measurements were
performed using a Cary 5,000 UV-Vis-NIR
Spectrophotometer (Agilent Technologies).
Animal model
The animal experiments were approved by the Danish
Animal Welfare Council, Ministry of Justice, and under-
taken in compliance with the directive 2010/63/EU of the
European Parliament on the protection of animals used for
scientiﬁc purposes. The animals used were 5-week-old
female BALB/c mice from Charles River Laboratories
(Wilmington, MA, USA). CT26 cells (ATCC) were
cultured in RPMI 1640+ GlutaMAX™ medium, supple-
mented with 10% fetal bovine serum and 1% penicillin-
streptomycin (Thermo Fisher Scientiﬁc) at 37°C and in 5%
CO2. When the cells reached ~70% conﬂuence they were
trypsinized and harvested. 3×105 cells (in 100 µL) were
injected into the left ﬂank of each mouse with a 27G
needle. Mice were kept under anesthesia throughout the
procedure by breathing 3–5% sevoﬂurane (Abbott
Scandinavia AB, Sweden) mixed with 35% O2 in N2.
Water and chow were available ad libitum. Animals were
observed daily, and the tumor size measured every second
or third day with a caliper. The tumor volume was calcu-
lated as: volume=½ (lengthxwidth2). When the tumors
reached 1,000 mm3 the animals were euthanized.
Photothermal therapy
Mice were injected with 190 μL of either NS (5x1010 NS/mL)
or saline through the tail vein 24 hours before the ﬁrst laser
treatment, as this is a standard time point used in the literature
with NS.12,28,33,34 They were kept anesthetized with sevoﬂur-
ane as previously described during the injection. The
following day, mice were placed on a platform below an 807-
nm laser beam (beam diameter of ~1 cm) and on a heating pad
to maintain their body temperature. The laser intensity used
was 1.2 W/cm2. During the 5-minute irradiation, the tempera-
ture on the tumor surface was recorded using real-time ther-
mographic imaging every 30 seconds (FLIR T-440 camera).
For protocols where more than one laser treatment was
applied, this process was repeated. When glycerol was
applied, it was swabbed on the tumor right before the laser
was turned on and after the treatment it was removed with
ethanol and water. The animals were provided pain relief with
temgesic (0.3 mg/mL) every 6–8 hours for 24 hours, starting
immediately before the treatment, to avoid unnecessary dis-
tress. It was also decided to allow 1 day of recovery in between
treatments due to the weight loss caused by the analgesia.35
Day 60 was considered the end of the study, and tumor free
animals were euthanized on this day. FLIR images were
analyzed within the software FLIR tools.
PET/CT
18F-FDG was produced at the Department of Clinical
Physiology, Nuclear Medicine, and PET, Rigshospitalet,
Centre of Diagnostic Investigations, Copenhagen,
Denmark. 18F-FDG PET scans were performed on
a MicroPET Focus 120 scanner (Concorde Microsystems
Inc., Knoxville, TN, USA) and CT scans were performed
on a nanoScan SPECT/CT scanner (Mediso Medical
Imaging Systems, Budapest, Hungary).
Approximately 10 MBq of 18F-FDG were injected into
the tail vein 1 hour before the PET scan. Mice were kept
anesthetized with sevoﬂurane throughout the duration of
the experiment, and their temperature maintained using
a heating pad. The parameters used for the CT scan were
the following: 720 projections, 300 ms of exposure time,
and 35 kVp of x-ray energy. The parameters for the PET
scan were: 300 seconds of acquisition time, energy win-
dow of 350–650 keV, and a timing window of 6 nanose-
conds. Raw PET data was post-processed into sinograms
and reconstructed using the maximum a posteriori (MAP)
algorithm. MicroPET and CT images were manually fused
using the Inveon software (Siemens Medical Solutions).
The activity in the tumor was quantiﬁed by deﬁning
a region of interest (ROI) on the fused PET/CT images.
Data analysis and statistics
Survival curves were created using the Kaplan-Meier
method, and median survival and hazard ratios (HR)
were compared using the log-rank test. Two-way
ANOVA with Tukey’s multiple comparisons test was
employed to compare the mean 18F-FDG uptake. The
mean maximum temperatures (at the last time point, 5
minutes) were compared using an unpaired two-
tailed t-test or one-way ANOVA. Correlations between
18F-FDG uptake and survival were calculated using linear
regression, and the 95% conﬁdence bands of the best-ﬁt
line were represented. The data was plotted in GraphPad
Prism7 and shown as mean±SEM (standard error of the
mean). Growth curves are shown until n=3.
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Results
Heating properties of NS
First, we examined in vitro the heating properties of NS at
different laser intensities, in the low range of what is com-
monly used for PTT.36,37 A solution of 5×109 NS/mL in
water was prepared in a plastic cuvette. The sample was
irradiated from the top for 10 minutes with a laser intensity
of 1.8, 1.5, or 1.2 W/cm2, after which it was allowed to cool
off for 10 minutes. With thermographic imaging we
observed that the maximum temperatures reached were
well above the threshold for induction of irreversible cellu-
lar damage for all laser intensities included (maximum
temperatures of ~69°C at 1.8 W/cm2, ~62°C at 1.5 W/
cm2, and ~58°C at 1.2 W/cm2, Figure 1A).
Following this, another sample was irradiated in four
cycles to test if the NS were photostable at these laser
intensities. Figure 1B shows that, using a laser intensity of
1.5 W/cm2, the sample could be reheated over intervals of 10
minutes, reaching maximum temperatures of ~65°C during
the ﬁrst cycle, ~66°C during the second, ~66°C during the
third, and ~66°C during the fourth cycle of irradiation.
Finally, we conﬁrmed the optical absorption properties of
the NS in the NIR region by measuring their UV-vis spec-
trum in a spectrophotometer (Figure 1C).
Glycerol as an index matching agent to
reduce unspeciﬁc heating
In our previous studies of PTT in tumor-bearing animals,27,33
it was observed that the laser in itself could induce an unspe-
ciﬁc temperature increase of ΔT ~10°C, which could likely be
attributed to laser attenuation in the dermal layer. In the early
literature of in vivo PTT, it was mentioned that glycerol, as an
index matching agent, can be swabbed onto the tumor prior to
irradiation to enhance transdermal laser penetration.11,12
Hence, we investigated if this method could reduce unspeciﬁc
heating for different tumor sizes. Tumor-bearing mice were
divided into three groups according to their tumor volumes;
100, 300, and 500 mm3 (±20 mm3 and n=4 for each group).
The mice were injected with 190 µL of saline through the tail
vein and after 24 hours irradiated for 5 minutes with NIR light
covering the whole tumor using a laser intensity of 1.5W/cm2.
Figure 2 shows the maximum temperature reached with and
without the use of glycerol on the tumor. Without applying
glycerol before irradiation (Figure 2A), the large tumors (ie,
500 mm3) reached a maximum temperature increase of ΔT
~20°C, and the smaller tumors (ie, 100 and 300 mm3) reached
ΔT ~10°C. When glycerol was applied (Figure 2B), the max-
imum temperatures reached by the 500 mm3 tumors were
reduced considerably (to ΔT ~10°C). In contrast, the smaller
tumors (100 and 300mm3) still reached a temperature increase
of ΔT ~10°C. This, however, occurred at a slower rate, which
also effectively reduces the integrated intensity and overall
accumulated damage.
Evaluation of two-dose fractionated
treatment in tumor-bearing mice
After studying the ability of the NS to be reheated and
optimizing laser penetration using glycerol, the ﬁrst protocol
for fractionated PTT that we investigated was a two-dose
fractionated treatment. Two groups of tumor-bearing mice
were established and underwent either one laser ablation
(NS1; n=5 and mean tumor size at baseline =143.2 mm3),
Figure 1 Heating of aqueous solution of NS under NIR light. (A) Thermographic imaging and temperature elevation as a function of time and laser intensity of a 5×109 NS/
mL aqueous solution of NS. The dashed line represents the top of the sample. (B) Temperature elevation of a 5×109 NS/mL aqueous solution of NS irradiated in four cycles
at a laser intensity of 1.5 W/cm2. Inset shows a TEM image of intact NS after second cycle of heating. (C) Absorption spectrum of NS measured in water.
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or two laser ablations with 1 day in between (NS2; n=6 and
mean tumor size at baseline=136.1 mm3). In addition, two
control groups were also included, representing tumor-
bearing mice injected with saline and irradiated once
(Saline1; n=8 and mean tumor size at baseline=126.7 mm3)
or twice with 1 day in between (Saline2; n=6 andmean tumor
size at baseline=120.4 mm3), and ﬁnally a sham group that
received NS but no photothermal ablation (Sham, n=6 and
mean tumor size at baseline=107.4 mm3). The experimental
timeline is shown in Figure 3A. All the animals were injected
with NS or saline 24 hours before the ﬁrst treatment, and
irradiated for 5 minutes with a laser intensity of 1.2 W/cm2.
Figure 2 Reduction of unspeciﬁc heating using glycerol. (A) Temperature elevation on the tumor surface in the absence of glycerol as a function of time and tumor size. (B)
Temperature elevation on the tumor surface in the presence of glycerol as a function of time and tumor size. Temperatures on the last time point (300 s) were compared
between the 500 mm3 and both smaller groups. ** Denotes a p value <0.01.
Abbreviation: ns, non-signiﬁcant.
Figure 3 Temperature response and treatment outcome using two doses of laser irradiation. (A) Experimental timeline, which includes a standard protocol receiving one
laser treatment on day 0 (dark blue) and a two-dose protocol receiving laser treatment on day 0 and day 2 (light blue). Both protocols consist of NS-laden tumors (group
receiving one dose: NS1, n=5; group receiving two doses: NS2, n=6), saline groups (group receiving one dose: Saline1, n=8; group receiving two doses: Saline2, n=6) and
a sham group (group receiving NS but no laser treatment, n=6). All animals are 18FDG PET/CT scanned the day before the ﬁrst PTTand 1 day after their last laser treatment.
(B) Temperature elevation during the ﬁrst laser dose of all animals. The maximum temperatures reached after 5 minutes were compared. For the ﬁrst treatment, both NS
groups together were compared against both saline groups. **** p<0.0001, *** p<0.001. (C) Temperature elevation during the second laser dose. Maximum temperatures
for NS2 and Saline2 were compared. (D) Tumor growth after treatment and (E) overall survival for all four groups. Tumor growth is plotted until n≥3 and data shown are
mean±SEM.
Dovepress Simón et al
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Shammicewere anesthetized for 5 minutes and placed on the
same treatment platform as animals in the NS and saline
groups, however, with the laser turned off. For early treat-
ment response evaluation, the mice were 18F-FDG PET/CT
scanned 1 day before treatment (baseline) and 1 day after
their last treatment (day 1 or day 3). Shammice were scanned
on baseline and day 3.
Using real-time thermographic imaging it was observed
that for the NS groups one laser treatment resulted in
a maximum temperature of around 50°C, whereas a second
laser treatment gave an approximately 10°C higher tempera-
ture (Figures 3B and C). For the saline groups, no differ-
ences in the maximum temperatures reached during the ﬁrst
and second ablation were observed. The 10°C higher tem-
perature measured during the second treatment compared to
the ﬁrst treatment in the NS groups was likely due to heating
of scabs on the tumors that often develop after PTT. Scabs
can heat more than regular tissue, and the FLIR camera
cannot distinguish the contribution of these two.
Following treatment, tumor size monitoring showed that
there were no signiﬁcant differences in tumor growth between
the different groups, but all NS and saline groups showed
inhibited tumor growth when compared to the sham group
(Figure 3D). This indicated that the laser per se also had
some effect. Additionally, the NS2 group did show a better
survival rate compared to the other groups (hazard ratio toNS1
group=0.47, 95% CI=0.1276–1.759, p=0.1; hazard ratio to
Saline1 group=0.52, 95% CI=0.1841–1.49, p=0.1; hazard
ratio to Saline2 group=0.43, 95% CI=0.1251–1.476, p=0.06,
and hazard ratio to sham group=0.33, 95%CI=0.09024–1.231,
p=0.0054, Figure 3E). This tendency was also supported by
18F-FDG PET/CT response evaluation. Figure 4A shows
representative images from the 18F-FDG PET/CT analysis,
where the effect of the treatment in the NS2 group is clearly
visualized as reduced 18F-FDG uptake in the tumor. Tumor
18F-FDG uptake was analyzed quantitatively and extracted as
%ID/g (percentage of injected dose per gram of tissue, Figure
4B). At baseline, all groups had comparative 18F-FDG uptake,
which also remained at the same level in both saline groups and
the sham group after treatment. After treatment, there was
a small reduction of around 20% in the 18F-FDG uptake for
theNS1 group compared to baseline.Meanwhile, the uptake in
the NS2 group was reduced signiﬁcantly (around 50%) in
comparison to all the other groups and to baseline levels.
The results for the NS2 group (improved survival rate
and 50% decrease of 18F-FDG uptake after treatment)
indicated that there was some effect of giving the second
treatment. In addition, we found a moderate and signiﬁcant
correlation between the 18F-FDG uptake ratio and survival
in the groups undergoing two treatments (Figure 4C;
r2=0.52, p=0.0083).
Evaluation of four-dose fractionated
treatment in tumor-bearing mice
Motivated by the observation that adding a second laser
treatment slowed down the tumor growth in some animals,
a second study was initiated where the mice underwent four
laser treatments separated by 1 day of recovery (ie, a full
protocol lasted 7 days; n=6 and mean tumor size at
Figure 4 PET-based treatment evaluation. (A) Representative 18F-FDG PET/CT images of NS, saline, and sham animals at baseline and after treatment. Arrows point to the
tumors. 1T=1 treatment, 2T=2 treatments. (B) The mean tumor 18F-FDG uptake at baseline and at day 1 or day 3 (NS group receiving one dose of irradiation: NS1, n=5; NS
group receiving two doses of irradiation: NS2, n=6; saline group receiving one dose of irradiation: Saline1, n=8; saline group receiving two doses of irradiation: Saline2, n=6;
sham group receiving NS but no irradiation: Sham, n=6). * p<0.05, *** p<0.001. Data shown are mean±SEM. (C) Correlation between 18F-FDG uptake ratio (baseline/day 3)
for animals in the NS2 and Saline2 groups.
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baseline=110.3 mm3, see Figure 5A). A control group receiv-
ing saline instead of NS was also included (n=7 and mean
tumor size at baseline=132.2 mm3). As before, all animals
were 18F-FDG PET/CT scanned 1 day before the ﬁrst treat-
ment (baseline) and 1 day after the last treatment (day 7).
Using thermographic imaging (Figure 5B), the maxi-
mum temperature was measured to be ~51°C (ﬁrst treat-
ment), ~49°C (second treatment), ~53°C (third treatment),
and ~51°C (fourth treatment) in the NS group. These
temperatures were signiﬁcantly higher than the ones
reached in the saline group, being ~43°C (ﬁrst treatment),
~41°C (second treatment), ~42°C (third treatment), and
~40°C (fourth treatment).
Despite a good temperature increase in all four
treatments, the tumor growth in the NS group did not
signiﬁcantly differ from the saline group (Figure 5C).
In addition, the survival was also not signiﬁcantly
different between the two groups, although there was
a tendency to increased survival in the NS group
(hazard ratio of 0.56, 95% CI=0.1835–1.697, p=0.2.
Figure 5D), and one NS-treated animal even showed
complete removal of the tumor (this mouse was eutha-
nized tumor-free on day 60).
18F-FDG PET/CT imaging was performed on day
−1 (baseline) and on day 7; representative images of
the 18F-FDG uptake before and after therapy are
shown in Figure 6A. The quantiﬁed mean 18F-FDG
uptake was comparable for the two groups on baseline
(Figure 6B). However, there was no signiﬁcant differ-
ence at day 7, either between the two groups or com-
pared to baseline. In spite of this, the 18F-FDG uptake
ratio again showed a moderate and signiﬁcant correla-
tion with survival (r2=0.49, p=0.0109, Figure 6C).
As the treatment response was fairly close to the response
from the two-dose fractionated PTT protocol, we would have
expected the mean 18F-FDG uptake to be similar as well.
However, in both our protocols it appears that the treatment
outcome is highly heterogeneous and probably dependent on
how well the tumors are treated during the ﬁrst and
maybe second round of PTT. We suspect that the tumors that
are insufﬁciently damaged in the beginning will also not ben-
eﬁt from subsequent treatments and recover within a week or
so. Hence, the lack of change in mean 18F-FDG uptake prob-
ably reﬂects that only two out of six animals showed increased
survival (see Figure 5D), and that the early effect of PTT on
18F-FDG uptake cannot be seen at a day 7 scan.
Figure 5 Temperature response and treatment outcome using four doses of laser irradiation. (A) Experimental timeline where the protocol consists of two groups
receiving either NS or saline which were laser treated four times with 1 day in between treatments. All animals were baseline scanned the day before PTT and 1 day after
their last PTT. (B) Temperature elevation during all four laser treatments in NS-laden tumors (NS, n=6) and the control group (Saline, n=7). The maximum temperatures
reached at the last time point (300 s) were compared. * p<0.05, ** p<0.01, and *** p<0.001. (C) Tumor growth after treatment, and (D) overall survival for both groups. Day
60 was considered the end of the study. Tumor growth is plotted until n≥3 and data shown are mean±SEM.
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Discussion
PTT relies on the ability of heat-generating nanoparticles
to selectively destroy malignant tissue when irradiated
with light, sparing surrounding healthy tissue. So naturally
optimizing the nanoparticle design, such that they accu-
mulate efﬁciently in tumors and generate light-induced
hyperthermic temperatures, has been the main focus in
the ﬁeld. At this point, however, it is becoming more and
more evident that optimizing the nanoparticles can only
improve the treatment outcome so much, and efﬁcacy
studies in particular in larger tumors are not looking very
promising with regard to PTT as a standalone
therapy.15,27,33 In contrast, the application of PTT in com-
bination with other therapies offers many opportunities to
obtain synergistic effects, and, hence, suggests that the
treatment protocol rather than the nanoparticles needs
optimization at this stage. A few studies using fractionated
PTT in mice have shown promising results,22–24 and moti-
vated by this we decided to evaluate two protocols where
tumor-bearing animals received either two or four laser
treatments, respectively.
First, we validated in vitro that the NS in aqueous
solutions could be heated at low laser irradiation, also
repeatedly. It is commonly seen in PTT that the laser in
itself induces a temperature increase of up to ~10°C.27,38
To attempt to reduce this, we applied glycerol to the tumor
surface, an index matching agent, and found that it could
reduce the laser-induced heating rate as well as suppress
unspeciﬁc heating. The effect was found to be more pro-
minent in larger tumors. Consequently, glycerol was
employed in all animal studies.
Despite reaching temperatures sufﬁcient for tissue
ablation in both fractionated PTT studies, the response
was only modest, and the number of laser treatments did
not have a signiﬁcant impact on tumor growth. Based on
these observations, we ﬁrst of all speculate that thermo-
graphic imaging might not be a suitable method for tumor-
temperature detection in fractionated PTT protocols, since
the measurements more likely represent the heating of
developed scabs, than elevated intratumoral temperatures.
The response was, however, fairly heterogeneous, and
a few animals did live longer in the groups receiving two
Figure 6 PET-based treatment evaluation. (A) Representative 18F-FDG PET/CT images of NS and saline-treated animals at baseline and after treatment. Arrows point to the
tumors. (B) The mean 18F-FDG tumor uptake at baseline and day 7 (NS group, n=6; saline group, n=6). Data shown are mean±SEM. (C) Correlation between 18F-FDG
uptake ratio (baseline/day 7) and survival for animals in the NS and saline groups.
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or four laser treatments, resulting in improved survival
rates compared to the group that only received a single
treatment. One mouse in the four-treatment group even
experienced complete tumor regression. The group sizes
in this study were comparable to other studies on PTT and
fractionated therapy.23,24 However, it should be noted that
at these group sizes the risk of type II statistical errors
make detection of smaller survival beneﬁts difﬁcult to
show.
Our ﬁndings are in contrast to another study conduct-
ing fractionated PTT in mice which reported great
response after four treatments using a laser intensity even
lower than the one used in this study, although in smaller
tumors.23 Hence, there are probably many factors that can
contribute to the treatment outcome, such as choice of
photothermal agent, tumor size at initiation of treatment,
laser dose, and treatment protocol. Also, the tumor model
we used in our study is rather fast-growing and it is likely
that fractionated PTT could be more efﬁcient in a less
aggressive and slower-growing tumor.
Another study in the literature conducting fractionated
PTT reported loss of effect after the ﬁrst treatment, prob-
ably owing to the clearance of nanoparticles from the
tumor.24 They were, however, able to solve this issue
using a spatially stable hydrogel that, after four treatments,
showed effective tumor suppression. It is possible that our
protocols, especially the one with four-treatments, also
suffer from tumor clearance of NS, and perhaps the out-
come could be improved if the animals were administered
with a second dose of nanoparticles during the treatment
period. However, treatment-induced edema or vessel
destruction in the tumor can be expected after therapy,39
and this will impair the tumor uptake of nanoparticles.
Also, nanoparticles are commonly coated with polyethy-
lene glycol (PEG) to improve blood circulation, but this
has been reported to induce an immune response and
accelerated clearance if administered multiple times.40–42
Therefore, it could also be of interest to evaluate nano-
shells functionalized with other types of coating than
PEG.43,44
Overall, fractionated PTT has only been applied in
a few studies, and more knowledge about how to optimize
the treatment protocol, eg number of treatments, laser
dose, duration, and appropriate tumor models, is needed.
Additionally, the use of thermographic imaging to measure
tumor temperatures might not be appropriate for detecting
the effect of PTT when working with multiple treatments.
Thus, other non-invasive imaging techniques such as PET/
CT imaging could be more suitable for evaluating and
optimizing treatment protocols for fractionated PTT.
Conclusion
Overall, in this study we found no signiﬁcant difference in
outcome between groups receiving PTT to tumors in frac-
tions compared to a single-dose approach, despite achiev-
ing temperatures during laser irradiation that were above
the limit for induction of irreversible damage.
Nevertheless, the outcome was heterogeneous, and a few
animals did respond to fractionated therapy, resulting in
improved survival rates compared to single-dose or con-
trol-treated animals. In addition, we also found that ther-
apy-induced changes in 18F-FDG uptake correlated with
survival, and we suggest that 18F-FDG PET/CT imaging
may be used for guiding the number of treatment sessions
necessary.
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